• If you are trying to figure out whether Travere Therapeutics at around US$27.92 is attractively priced or not, you will want to see how its current value stacks up against a few different yardsticks.
• The stock has returned 0.7% over the past week, while the 30 day return is a 9.6% decline and the year to date return is a 29.4% decline. This is set against a 37.1% return over the last year and 26.4% over three years.
• Those mixed returns have come as investors weigh recent company specific news and the broader mood around biotech names, which can quickly affect risk perception. For you, that backdrop makes it even more important to separate short term swings from what the current share price might imply about the long term.
• On Simply Wall St's 6 point valuation checklist, Travere Therapeutics currently scores a full 6 out of 6. Next up is a walk through the main valuation approaches used to reach that conclusion and how these compare with an even richer way to think about value that is covered at the end of this article.

Approach 1: Travere Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today, using a required rate of return. It focuses on the cash that might ultimately be available to shareholders.

For Travere Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about $75.9 million. Analysts provide specific free cash flow estimates for the next several years, such as $49.3 million in 2026 and $131.5 million in 2027, with further projections running out to a forecast of $458.7 million in 2030. Beyond the analyst horizon, Simply Wall St extrapolates additional years of free cash flow to complete the model.

Adding up these discounted projections gives an estimated intrinsic value of about $122.20 per share. Compared with the current share price of around $27.92, this DCF output suggests the stock trades at a 77.2% discount to that estimate, which points to a wide valuation gap.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Travere Therapeutics is undervalued by 77.2%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.

Approach 2: Travere Therapeutics Price vs Sales

For companies where earnings are negative or still developing, the P/S ratio is often more useful than P/E because it compares what the market is paying for each dollar of revenue rather than profit. Investors usually accept a higher or lower P/S ratio depending on what they expect for future growth and how risky they feel the business is, so there is no single “correct” level.

Travere Therapeutics currently trades on a P/S ratio of 5.25x. This is close to the peer average of 5.25x and below the wider Biotechs industry average P/S of 10.79x. Simply Wall St also calculates a proprietary “Fair Ratio” for Travere Therapeutics, which is 5.81x. This Fair Ratio is intended to reflect the P/S level that might be expected after factoring in the company’s earnings growth profile, industry, profit margins, market cap and specific risks.

Compared with a simple peer or industry comparison, the Fair Ratio provides a more tailored yardstick because it adjusts for company specific characteristics rather than relying on broad sector averages. Setting this 5.81x Fair Ratio against the current 5.25x P/S suggests Travere Therapeutics shares are trading below that model based reference point.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Travere Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so here is Narratives, a simple tool on Simply Wall St's Community page that lets you attach a clear story about Travere Therapeutics to the numbers you think are reasonable for its future revenue, earnings, margins and Fair Value. You can then compare that Fair Value to the current price and see, in real time, how your view stacks up against others, from a bullish Narrative that might see Fair Value around US$49.00 to a cautious one closer to US$32.41 or even US$20.00. All of these automatically refresh when new news or earnings arrive, so you can use the story you believe in to decide whether the current market price looks high, low, or about fair for you.

Do you think there's more to the story for Travere Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.